Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
“In the early 1990s, the potential for using alkaline phosphatase (RESCAP®) to detoxify bacterial toxins was discovered. We proposed that this enzyme could be a simple treatment for various diseases and medical applications. As more scientists and clinicians came to share this belief in its potential, We were motivated to continue developing RESCAP®. Today, clinicians, investors, and employees continue to be encouraged by the potential of RESCAP® due to the abundance of pre-clinical and clinical research publications and our positive interim phase 2b results with RESCAP®”
RESCAP® (rescuing alkaline phosphatase) is the proprietary name for our medication based on the enzyme alkaline phosphatase (AP), naturally present in the body and part of the innate immune system (‘first line of defence’).
RESCAP® is a therapeutic designed to expedite the recovery process for critical care patients. The use of RESCAP® has been shown to significantly reduce the time it takes for patients in the ICU to stabilize and to lower the occurrence of severe complications, thereby improving their chances of recovery.
RESCAP® intervention has the potential to prevent inflammation.
Therefore, RESCAP® restores the normal homeostasis and thus will accelerate recovery of patients in the ICU.
RESCAP® intervention has the potential to prevent and restore leaky boundaries
RESCAP® intervention has the potential to prevent ischemia-induced organ damage
RESCAP® is a therapeutic designed to expedite the recovery process for critical care patients. The use of RESCAP® has been shown to significantly reduce the time it takes for patients in the ICU to stabilize and to lower the occurrence of severe complications, thereby improving their chances of recovery.
RESCAP® intervention has the potential to prevent inflammation.
RESCAP® intervention has the potential to prevent and restore leaky boundaries
RESCAP® intervention has the potential to prevent ischemia-induced organ damage
Therefore, RESCAP® restores the normal homeostasis and thus will accelerate recovery of patients in the ICU.
The Alloksys team is committed to bringing RESCAP® to market and making it widely available for those who could benefit from it.
President
CFO
CSO
Scientific Director
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
